Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis

BACKGROUND: Hyperuricemia and gout have become public health concerns; many important guidelines have recommended xanthine oxidase inhibitors (XOIs) as the first-line urate-lowering therapies (ULTs) to treat chronic gout with hyperuricemia. However, whether treating hyperuricemia and gout with ULTs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Li, Cao, Ling, Zhao, Tian-Yi, Yang, Xue, Zhu, Xiao-Xia, Zou, He-Jian, Wan, Wei-Guo, Xue, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Meta Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176444/
https://www.ncbi.nlm.nih.gov/pubmed/32106120
http://dx.doi.org/10.1097/CM9.0000000000000682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176444/
https://www.ncbi.nlm.nih.gov/pubmed/32106120
http://dx.doi.org/10.1097/CM9.0000000000000682

Ejemplares similares